rutin and adriamycinol

rutin has been researched along with adriamycinol* in 1 studies

Other Studies

1 other study(ies) available for rutin and adriamycinol

Article	Year
The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice. Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:4 Monohydroxyethylrutoside (monoHER) has proved to be a good protector against doxorubicin-induced cardiotoxicity without interfering with the antitumor effect of doxorubicin. The aim of the present study was to determine whether there is a pharmacokinetic interaction between monoHER and doxorubicin which may be involved in monoHER cardioprotection.. Mice were treated with monoHER (500 mg x kg(-1) i.v.) alone, monoHER 5 min after doxorubicin (10 mg x kg(-1) i.v.), doxorubicin alone and doxorubicin 5 min after monoHER. The levels of monoHER and doxorubicin(ol) in plasma and heart tissue were measured by HPLC 24 h and 48 h after monoHER and doxorubicin administration, respectively.. The areas under the concentration-time curves (AUCs) of monoHER and doxorubicin(ol) were not affected by the coadministered drug. No changes were observed in pharmacokinetic parameters such as initial and final half-lives, mean residence time, clearance and volume of distribution of monoHER and doxorubicin(ol) after single or combined administration.. The cardioprotection of monoHER in mice is not caused by a pharmacokinetic interaction between monoHER and doxorubicin. Topics: Animals; Area Under Curve; Cardiotonic Agents; Doxorubicin; Drug Interactions; Drug Therapy, Combination; Half-Life; Hydroxyethylrutoside; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Myocardium; Tissue Distribution	2003

Article

Year

The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.

Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:4

Monohydroxyethylrutoside (monoHER) has proved to be a good protector against doxorubicin-induced cardiotoxicity without interfering with the antitumor effect of doxorubicin. The aim of the present study was to determine whether there is a pharmacokinetic interaction between monoHER and doxorubicin which may be involved in monoHER cardioprotection.. Mice were treated with monoHER (500 mg x kg(-1) i.v.) alone, monoHER 5 min after doxorubicin (10 mg x kg(-1) i.v.), doxorubicin alone and doxorubicin 5 min after monoHER. The levels of monoHER and doxorubicin(ol) in plasma and heart tissue were measured by HPLC 24 h and 48 h after monoHER and doxorubicin administration, respectively.. The areas under the concentration-time curves (AUCs) of monoHER and doxorubicin(ol) were not affected by the coadministered drug. No changes were observed in pharmacokinetic parameters such as initial and final half-lives, mean residence time, clearance and volume of distribution of monoHER and doxorubicin(ol) after single or combined administration.. The cardioprotection of monoHER in mice is not caused by a pharmacokinetic interaction between monoHER and doxorubicin.

Topics: Animals; Area Under Curve; Cardiotonic Agents; Doxorubicin; Drug Interactions; Drug Therapy, Combination; Half-Life; Hydroxyethylrutoside; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Myocardium; Tissue Distribution

2003